Summit Therapeutics (SMMT) finds itself at a crossroads, with its stock down over 30% in the past year. Conflicting signals from valuation models paint a complex picture: is the biotech firm dramatically overvalued on traditional metrics, or deeply undervalued based on future cash flows?
From a record-breaking public health crisis in South Carolina to a stunning archaeological find in Mexico, here are the major developments you need to know this afternoon, alongside a look at how global politics is reshaping daily life from Havana to your local coffee shop.
Federal officials have issued provisional approval to relocate 30 beluga whales and four dolphins from the shuttered Ontario park to accredited U.S. aquariums, averting an immediate euthanasia threat pending final health and care plans.
Lawmakers are negotiating a short-term deal to fund the Department of Homeland Security, aiming to avoid a partial government shutdown this weekend. The talks occur against the backdrop of heightened political pressure following recent violence in Minneapolis and a shift in the administration's enforcement rhetoric.
A new Fox News survey reveals Democrats leading Republicans 52% to 46% in a generic congressional ballot for the 2026 midterms, the highest level of support recorded for either party in this poll series. Voter priorities and sharp partisan divides on key issues shape the early political landscape.
In a new court filing, Hunter Biden's legal team moves to dismiss a contempt motion brought by the mother of his 7-year-old daughter, arguing his relationship with the child is legally irrelevant and denying violations of their 2023 support agreement.
Foreign women detained in Syria's Roj camp, linked to the Islamic State group, see a potential path to freedom following a government offensive that weakened their Kurdish guards. As political dynamics shift, their hopes for amnesty or repatriation collide with international reluctance and an uncertain future for the camps.
New analysis from NRC Health reveals that integrating real-time patient sentiment tools like Net Promoter Score with traditional HCAHPS surveys can accelerate improvements in care quality and directly impact Medicare reimbursements under value-based programs.
Intuitive Machines (LUNR) is set to acquire Lanteris Space Systems in an $800 million deal, expanding its capabilities into vertically integrated space infrastructure. Concurrently, NASA has selected the company to provide critical tracking support for the upcoming Artemis II crewed lunar mission, signaling growing trust in its technical prowess.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
A fresh round of analyst price target adjustments for European asset manager Amundi (ENXTPA:AMUN) is prompting investors to recalibrate their expectations, placing renewed scrutiny on the firm's growth trajectory in a challenging macroeconomic climate.
Blue Owl Capital faces a wave of securities class actions alleging disclosure failures around liquidity and redemptions, casting a shadow over its robust alternative asset management platform. As legal pressures mount, the market weighs solid analyst backing against growing governance concerns, setting the stage for a pivotal earnings report.
Amidst broader market volatility, a closer look reveals compelling opportunities in the UK's penny stock arena. We analyze three companies—Accesso Technology, ActiveOps, and Zotefoams—that combine niche market strength with evolving financial narratives for the discerning investor.
Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
The French government has intervened to stop satellite operator Eutelsat from selling its ground antenna assets, framing the move as a defense of European strategic autonomy against rivals like SpaceX's Starlink.
The long-standing pillar of UK e-commerce—free and unlimited returns—is facing a fundamental overhaul as soaring costs and changing consumer habits force retailers to adopt more targeted and sustainable policies.
Parker-Hannifin posts record-breaking Q2 fiscal 2026 results, fueled by robust organic growth and margin expansion, particularly in aerospace. The industrial giant raises full-year guidance and details strategic progress on its planned acquisition of Filtration Group Corporation.
